BOSTON--(BUSINESS WIRE)--Cerveau Technologies Inc. today announced a licensing agreement with Alector, in which Cerveau will provide its investigational imaging agent (MK-6240) to Alector for use in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs, made up of aggregated tau protein, are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.
Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases, including two Alzheimer’s disease programs currently in the clinic. The collaboration is focused on using MK-6240 as an exploratory biomarker in Alector’s research studies.
“Cerveau is excited to be working with Alector to better understand Tau pathology,” said Rick Hiatt, President of Cerveau Technologies, Inc., “The partnership with Alector is another important step forward in our strategy of developing an international network of key collaborators and production sites to enable broad access for scientific research and clinical trial support.”
About Cerveau Technologies, Inc.
Cerveau's vision is to globally develop diagnostics and technology that positively impact patients with neurodegenerative disorders including Alzheimer's disease.